Publikationen in Zusammenarbeit mit Forschern von Brigham and Women's Hospital (9)

2019

  1. Dapagliflozin and cardiovascular outcomes in type 2 diabetes

    New England Journal of Medicine, Vol. 380, Núm. 4, pp. 347-357

  2. Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial

    The Lancet Diabetes and Endocrinology, Vol. 7, Núm. 8, pp. 618-628

  3. Ticagrelor in patients with diabetes and stable coronary artery disease with a history of previous percutaneous coronary intervention (THEMIS-PCI): a phase 3, placebo-controlled, randomised trial

    The Lancet, Vol. 394, Núm. 10204, pp. 1169-1180

2018

  1. Alirocumab and cardiovascular outcomes after acute coronary syndrome

    New England Journal of Medicine, Vol. 379, Núm. 22, pp. 2097-2107

2017

  1. Cangrelor With and Without Glycoprotein IIb/IIIa Inhibitors in Patients Undergoing Percutaneous Coronary Intervention

    Journal of the American College of Cardiology, Vol. 69, Núm. 2, pp. 176-185

  2. Cardiovascular efficacy and safety of bococizumab in high-risk patients

    New England Journal of Medicine, Vol. 376, Núm. 16, pp. 1527-1539

  3. Evolocumab and clinical outcomes in patients with cardiovascular disease

    New England Journal of Medicine, Vol. 376, Núm. 18, pp. 1713-1722

2015

  1. Does sex affect anticoagulant use for stroke prevention in nonvalvular atrial fibrillation?: The prospective global anticoagulant registry in the FIELD-Atrial Fibrillation

    Circulation: Cardiovascular Quality and Outcomes, Vol. 8, pp. S12-S20

2013

  1. Edoxaban versus warfarin in patients with atrial fibrillation

    New England Journal of Medicine, Vol. 369, Núm. 22, pp. 2093-2104